New cancer drug M3554 targets tough tumors in first human trial

NCT ID NCT06641908

Recruiting now Disease control Sponsor: EMD Serono Research & Development Institute, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new drug called M3554, which is designed to seek out and attack cancer cells that have a protein called GD2 on their surface. The study will include up to 52 people with advanced soft tissue sarcoma or glioblastoma that has not responded to prior treatments. The main goals are to find a safe dose and check for any early signs that the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: M3554 (an antibody-drug conjugate that targets GD2, a protein on some cancer cells, to deliver a chemotherapy-like drug directly to the tumor)
What this could lead to: If it works, this could point toward a new treatment option for advanced soft tissue sarcoma and glioblastoma that have not responded to standard therapies.
What could go wrong: This is a very early, first-in-human Phase 1 trial with only 52 participants, so safety and dosing are still being figured out. It may not shrink tumors or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Centre Antoine Lacassagne - Service d'Hématologie Oncologie
RECRUITING

Nice, France
Centre Leon Berard - Service d'Oncologie Medicale
RECRUITING

Lyon, France
Centre Oscar Lambret - cancerologie generale
RECRUITING

Lille, France
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Institut Bergonié - Service d'Oncologie Médicale
RECRUITING

Bordeaux, France
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc
WITHDRAWN

New York, New York, 10022, United States
National Cancer Center Hospital
RECRUITING

Chūōku, Japan
Royal Marsden Hospital-Sutton - Dept of Oncology (Surrey)
RECRUITING

Sutton, Surrey, SM2 5PT, United Kingdom
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
UZ Leuven
RECRUITING

Leuven, Belgium
Universitaetsspital Zuerich - Klinik fuer Neurologie
RECRUITING

Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.